Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Atezolizumab + GDC-0919||Phase I||Actionable||In a Phase I trial, GDC-0919 (Navoximod) and Tecentriq (atezolizumab) combination therapy was well tolerated, resulted in stable disease as best response in 80% (8/10) of patients with advanced solid tumors (PMID: 31124055).||31124055|
|Unknown unknown||Advanced Solid Tumor||not applicable||Atezolizumab + GDC-0919||Phase I||Actionable||In a Phase I trial, treatment with GDC-0919 and Tecentriq (atezolizumab) in combination was well-tolerated and demonstrated preliminary anti-tumor activity in patients with advanced solid tumors, with partial response in 9% (4/45) and stable disease in 24% (11/45) of patients (J Clin Oncol 35, 2017 (suppl; abstr 105)).||detail...|
|PubMed Id||Reference Title||Details|
|A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.||Full reference...|
|(31124055)||Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.||Full reference...|